ORBIMED Sells $125M TERN Stake After 858% Surge

Feb 20, 2026

Bobby Quant Team

💡 Key Takeaway

Major investor ORBIMED took profits on TERN after explosive gains, signaling potential peak valuation ahead of critical clinical data.

What Happened: ORBIMED's Strategic TERN Reduction

ORBIMED Advisors sold 5.4 million shares of Terns Pharmaceuticals (TERN) worth approximately $125 million in Q4 2025, according to an SEC filing. The transaction reduced ORBIMED's stake from over 7.5 million shares to just over 2.1 million shares remaining. This sell-off occurred after TERN stock delivered an extraordinary 858% return over the past year, dramatically outperforming the S&P 500.

The timing is significant as TERN shares reached $39.58 at the time of the filing, representing a massive valuation surge for a clinical-stage biotech company. ORBIMED maintained a smaller position worth approximately $85 million, indicating they haven't completely exited their investment.

Despite the substantial sale, TERN still represented 1.78% of ORBIMED's reportable assets under management after the transaction. The fund's top holdings include EWTX, LLY, and BSX, showing a diversified biotech and healthcare portfolio.

TERN's market capitalization now stands at $4.29 billion despite reporting negative net income of $94.44 million over the trailing twelve months. This disconnect highlights the speculative nature of clinical-stage biotech investing where valuations depend entirely on pipeline potential rather than current financials.

What This Means for Me

If you hold TERN, consider taking partial profits like ORBIMED did to lock in gains while maintaining some upside exposure. Investors with biotech sector exposure should monitor how this profit-taking behavior might signal broader valuation concerns in high-flying clinical-stage names. Those holding LLY or EW can take comfort that ORBIMED maintains significant positions in these established healthcare leaders.

Why It Matters: Profit-Taking Signals Valuation Concerns

When a sophisticated healthcare investor like ORBIMED takes profits of this magnitude, it often signals they believe the stock has reached full valuation or that risk-reward has become less favorable. ORBIMED's partial exit suggests they're locking in gains while maintaining some exposure to TERN's upside potential.

For TERN specifically, the timing is crucial as the company approaches important clinical milestones for its NASH and obesity pipeline. The 858% rally priced in significant success, meaning any clinical setbacks could trigger substantial downside. ORBIMED's move might indicate they want to reduce risk ahead of binary trial results.

The transaction highlights the delicate balance biotech investors face between riding momentum and managing risk. While TERN's story remains compelling with multiple clinical candidates, the valuation now demands near-perfect execution and positive data readouts.

For the broader biotech sector, ORBIMED's continued large positions in established players like Lilly (LLY) and Edwards Lifesciences (EW) suggests they favor companies with proven revenue streams alongside their speculative biotech bets. This balanced approach might offer lessons for retail investors navigating high-risk, high-reward healthcare investments.

Stock to Watch

Stocks	Impact	Analysis
TERN	Neutral	ORBIMED's partial profit-taking suggests caution after massive gains, but maintained position shows ongoing belief in pipeline potential ahead of clinical data.
LLY	Positive	As ORBIMED's second-largest holding, the maintained $323 million position signals strong confidence in Lilly's established diabetes and obesity franchise.
EW	Positive	Included in ORBIMED's top five holdings, indicating conviction in Edwards Lifesciences' structural heart business and growth prospects.

Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.